

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

AMNEAL PHARMACEUTICALS LLC and AMNEAL
PHARMACEUTICALS OF NEW YORK, LLC,
Petitioners,

v.

ALMIRALL, LLC
Patent Owner

Case: IPR2018-00608

U.S. Patent No. 9,161,926

**SECOND DECLARATION OF BOZENA B. MICHNIAK-KOHN, Ph.D.,
FAAPS, M.R.Pharm.S.**

AMN1050

Amneal v. Almirall LLC

*Inter Partes Review of U.S. Patent No. 9,161,926
Second Declaration of Bozena B. Michniak-Kohn, Ph.D., FAAPS,
M.R.Pharm.S. (Exhibit 1050)*

I, Bozena B. Michniak-Kohn, do hereby declare as follows:

I. Introduction

1. I am over the age of 18 and otherwise competent to make this declaration. I have been retained as an expert on behalf of Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York, LLC (“Amneal”). I understand this declaration is being submitted in an *Inter Partes* Review (“IPR”) proceeding concerning claims 1-6 of U.S. Patent No. 9,161,926 (“the ’926 patent”) (AMN1001). I am being compensated for my time in connection with this IPR at my standard legal consultant rate of \$650/hr. I have no personal or financial interest in Amneal or in the outcome of this proceeding.

2. I have previously submitted a declaration in this IPR.

II. Basis for my opinion

3. In arriving at my opinion below, I considered Dr. Klibanov’s Declaration (Ex. 2003) as well as certain documents cited in Dr. Klibanov’s declaration, and the documents cited herein.

III. A construction of “dapsonе” is not necessary as Garrett discloses the claimed “dapsonе” and a POSA would understand the amounts of dapsonе shown in Garrett would apply to 4-4’diaminodiphenyl sulfone.

4. Dr. Klibanov argues that the challenged claims are limited to a specific “dapsonе” chemical name: 4,4’-diaminodiphenyl sulfone. Ex. 2003, ¶¶142-43.

Inter Partes Review of U.S. Patent No. 9,161,926
Second Declaration of Bozena B. Michniak-Kohn, Ph.D., FAAPS,
M.R.Pharm.S. (Exhibit 1050)

5. A POSA would have understood from the prior art that dapsons has the chemical formula $C_{12}H_{12}N_2O_2$ and can be referred to as 4,4'-diaminodiphenyl sulfone or 4,4'-sulfonyldianiline or bis (4-aminophenyl)sulfone. AMN1007, [0022]; AMN1004, 8:17-22; AMN1010, 1. The fact that the '926 patent says "[d]apsons (4,4'-diaminophenyl sulfone)" (AMN1001, 2:6) would simply be understood by a POSA to refer to dapsons generally, and would not have been understood to exclude synonymous chemical names for dapsons.

6. Next, Dr. Klivanov argues that (1) Garrett does not disclose the claimed "dapsons" structure and (2) a POSA would not understand Garrett's teaching of using about 5% to 10% w/w dapsons in a topical composition would apply to the claimed "dapsons." Ex. 2003, ¶¶79, 82-85, 142, 148. I disagree. Regardless of whether the claimed "dapsons" was limited to the compound 4-4'-diaminodiphenyl sulfone, Garrett discloses this compound and teaches that the amount taught in Garrett would apply to this compound.

7. First, Garrett says that "'dapsons' refers to the chemical compound dapsons having the chemical formula $C_{12}H_{12}N_2O_2S$ as well as bis(4-aminophenyl)sulfone, 4'4'-diaminodiphenyl sulfone, and its hydrates ... dapsons analogs, and dapsons related compounds." AMN1004, 8:18-22 (emphasis added). From this disclosure a POSA would understand that 4'4'-diaminodiphenyl sulfone is the claimed compound that Dr. Klivanov seeks to limit the claimed "dapsons"

*Inter Partes Review of U.S. Patent No. 9,161,926
Second Declaration of Bozena B. Michniak-Kohn, Ph.D., FAAPS,
M.R.Pharm.S. (Exhibit 1050)*

to.¹ Moreover, Garrett discloses the chemical structure of dapsone “C₁₂H₁₂N₂O₂S” and then identifies several different ways of identifying that structure using different naming conventions (“bis(4-aminophenyl)sulfone” versus “4’4’-diaminodiphenyl sulfone”) but a POSA would understand these chemical names to be synonyms because they are referring to the same chemical structure. It appears that Dr. Klibanov agrees. AMN1004, 8:18-27, 10:28-31; Ex. 2003, ¶47. And the “dapsone analogs” and “dapsone related compounds” in Garrett are derived from that same basic chemical structure, so if a POSA were considering “dapsone analogs” or “dapsone related compounds” she would additionally envisage the 4,4-diaminodiphenyl sulfone structure. AMN1004, 8:22-27.

¹ The only difference between the “4’4’-diaminodiphenyl sulfone” structure in Garrett and Almirall’s proposed construction is the first apostrophe which is bolded for emphasis: **4’4’**-diaminodiphenyl sulfone. Dr. Klibanov does not appear to argue that this difference is meaningful, and a POSA would not consider it so, because the apostrophe in the chemical name merely conveys that each phenyl ring contains an amino group at the 4-position. Because both amino groups in the structure could not be located at the same 4-position, a POSA would be able to understand the chemical structure regardless of the added apostrophe.

Inter Partes Review of U.S. Patent No. 9,161,926
Second Declaration of Bozena B. Michniak-Kohn, Ph.D., FAAPS,
M.R.Pharm.S. (Exhibit 1050)

8. Second, a POSA would understand that the amount of dapsone disclosed by Garrett would apply to the 4,4'-diaminodiphenyl sulfone compound. Throughout Garrett, it distinguishes between “dapsone” and “dapsone analogs and related compounds.” Garrett says that ACZONE Gel, 5% is “a topical formulation of *dapsone*” and that it is approved by Food and Drug Administration (“FDA”) to treat acne vulgaris. AMN1004, 10:6-9 (emphasis added). Garrett also says that “dapsone” was first synthesized in 1908. AMN1004, 10:27-28. Conversely, Garrett later describes “dapsone analogs and related compounds” and discusses activity and toxicity comparison testing *against dapsone*. AMN1004, 11:1-12. From these disclosures, and notwithstanding Garrett’s definition of “dapsone,” a POSA would have understood that when Garrett simply refers to “dapsone,” it means the 4,4'-diaminodiphenyl sulfone compound. Accordingly, a POSA would consider Garrett’s disclosure of compositions containing about 5% to 10% w/w dapsone to apply to the 4,4'-diaminodiphenyl sulfone structure.

9. Third, of the compounds encompassed by Garrett’s definition of “dapsone,” the 4,4'-diaminodiphenyl sulfone compound was the only one approved by FDA for the treatment of acne, thus Garrett’s disclosure of using topical compositions containing “about 5% to 10% dapsone,” which encompasses the FDA-approved amount of 4,4'-diaminodiphenyl sulfone, would have been understood by a POSA to apply to the 4,4'-diaminodiphenyl sulfone compound.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.